Rallybio Corp. (RLYB)
16.94
+0.25
(+1.50%)
USD |
NASDAQ |
Sep 02, 16:00
17.05
+0.11
(+0.65%)
After-Hours: 20:00
Rallybio Research and Development Expense (TTM) : 7.384M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.384M |
| March 31, 2026 | 11.48M |
| December 31, 2025 | 17.10M |
| September 30, 2025 | 20.81M |
| June 30, 2025 | 26.11M |
| March 31, 2025 | 34.17M |
| December 31, 2024 | 41.38M |
| September 30, 2024 | 49.91M |
| June 30, 2024 | 54.95M |
| March 31, 2024 | 55.13M |
| December 31, 2023 | 53.39M |
| September 30, 2023 | 48.26M |
| Date | Value |
|---|---|
| June 30, 2023 | 47.08M |
| March 31, 2023 | 44.08M |
| December 31, 2022 | 40.52M |
| September 30, 2022 | 35.83M |
| June 30, 2022 | 28.69M |
| March 31, 2022 | 25.39M |
| December 31, 2021 | 26.80M |
| September 30, 2021 | 28.22M |
| June 30, 2021 | 28.40M |
| March 31, 2021 | 24.68M |
| December 31, 2020 | 17.57M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Q32 Bio, Inc. | 14.35M |
| Beam Therapeutics, Inc. | 408.66M |
| C4 Therapeutics, Inc. | 100.05M |
| Cullinan Therapeutics, Inc. | 171.47M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |